Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine.
Sarinya BoongirdPiyatida ChuengsamanChavachol SetthaudomArkom NongnuchMontira AssanathamSalinnart PhanprasertRungthiwa KitpermkiatSasisopin KiertiburanakulKumthorn MalathumAngsana PhuphuakratAndrew DavenportJackrapong BruminhentPublished in: Infectious diseases and therapy (2021)
Patients with ESKD could develop similar SARS-CoV-2-specific cell-mediated immune responses compared to healthy controls, although suboptimal humoral immune responses were observed following two doses of SARS-CoV-2 vaccination. Therefore, patients with ESKD and the abovementioned factors are at risk of generating inadequate humoral immune responses, and a vaccine strategy to elicit greater immunogenicity among these relatively immunocompromised patients is warranted. (Thai Clinical Trials Registry, TCTR20210226002).
Keyphrases
- immune response
- sars cov
- respiratory syndrome coronavirus
- clinical trial
- end stage renal disease
- dendritic cells
- toll like receptor
- newly diagnosed
- ejection fraction
- single cell
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- stem cells
- intensive care unit
- cell therapy
- mesenchymal stem cells
- inflammatory response
- extracorporeal membrane oxygenation
- phase iii
- study protocol
- respiratory failure